{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:15Z","timestamp":1793383155052,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The purpose of this study was to determine if vertebral body and splenic dosimetry was associated with the development of lymphopenia in patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC) treated with stereotactic body radiation therapy (SBRT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with BRPC\/LAPC who were treated with SBRT and who had lymphocyte counts and radiation treatment plans available for review were included in the study. Vertebral body levels T11-L3 and the spleen were retrospectively contoured for each patient. Univariate (UVA) and multivariable analyses (MVA) were performed to identify associations between vertebral body and splenic dosimetric parameters with absolute lymphocyte count (ALC) and grade\u2009\u2265\u20092 lymphopenia. Receiver operator characteristic curves were generated to identify dose-volume thresholds in predicting grade\u2009\u2265\u20092 lymphopenia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 132 patients were included in the study. On UVA and MVA, vertebral V15 (regression coefficient [\u03b2]: \u2212\u20090.026, 95% CI \u2212\u20090.044 to \u2212\u20090.009, <jats:italic>p<\/jats:italic>\u2009=\u20090.003), vertebral V2.5 (\u03b2: \u2212\u20090.011, 95% CI \u2212\u20090.020 to \u2212\u20090.002, <jats:italic>p<\/jats:italic>\u2009=\u20090.015), and log<jats:sub>10<\/jats:sub>PTV (\u03b2: \u2212\u20090.15, 95% CI \u2212\u20090.30 to \u2212\u20090.005, <jats:italic>p<\/jats:italic>\u2009=\u20090.042) were associated with post-SBRT ALC. On UVA and MVA, vertebral V15 (odds ratio [OR]: 3.98, 95% CI 1.09\u201314.51, <jats:italic>p<\/jats:italic>\u2009=\u20090.027), vertebral V2.5 (OR: 1.04, 95% CI 1.00\u20131.09, <jats:italic>p<\/jats:italic>\u2009=\u20090.032), and spleen V10 (OR: 1.05, 95% CI 1.09\u20131.95, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) were associated with development of grade\u2009\u2265\u20092 lymphopenia. Development of grade\u2009\u2265\u20092 lymphopenia was more likely in patients with vertebral V15\u2009\u2265\u20095.84% (65.5% vs 34.0%, <jats:italic>p<\/jats:italic>\u2009=\u20090.002), vertebral V2.5\u2009\u2265\u200948.36% (48.9% vs 23.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.005), and spleen V10\u2009\u2265\u20094.17% (56.2% vs 26.9%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Increasing radiation dose to vertebral bodies and spleen were associated with the development of lymphopenia in BRPC\/LAPC treated with SBRT. Optimization of vertebral body and splenic dosimetry may reduce the risk of developing lymphopenia and improve clinical outcomes in this population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-021-01969-1","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T18:02:43Z","timestamp":1640368963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9209-2923","authenticated-orcid":false,"given":"Abhinav V.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Deek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchi","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol K.","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"1969_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1969_CR2","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913\u201321.","journal-title":"Cancer Res"},{"key":"1969_CR3","unstructured":"National Comprehensive Cancer Network. Pancreatic Adenocarcinoma. Version 2.2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic_blocks.pdf. Accessed 18 Sept 2021."},{"key":"1969_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10\u201327.","journal-title":"World J Oncol"},{"key":"1969_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/07357907.2013.767342","volume":"31","author":"JL Campian","year":"2013","unstructured":"Campian JL, Ye X, Brock M, et al. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Investig. 2013;31:183\u20138.","journal-title":"Cancer Investig"},{"key":"1969_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3109\/07357907.2012.700987","volume":"30","author":"A Balmanoukian","year":"2012","unstructured":"Balmanoukian A, Ye X, Herman J, et al. The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Investig. 2012;30:571\u20136.","journal-title":"Cancer Investig"},{"key":"1969_CR7","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/hed.23535","volume":"36","author":"J Campian","year":"2014","unstructured":"Campian J, Sarai G, Ye X, et al. The association between severe treatment-related lymphopenia and progression free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck. 2014;36:1747\u201353.","journal-title":"Head Neck"},{"key":"1969_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.adro.2020.03.021","volume":"5","author":"TH So","year":"2020","unstructured":"So TH, Chan SK, Chan WL, et al. Lymphopenia and radiation dose to circulating lymphocytes with neoadjuvant chemoradiation in esophageal squamous cell carcinoma. Adv Radiat Oncol. 2020;5:880\u20138.","journal-title":"Adv Radiat Oncol"},{"key":"1969_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","volume":"123","author":"BP Venkatesulu","year":"2018","unstructured":"Venkatesulu BP, Mallick S, Lin SH, et al. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol. 2018;123:42\u201351.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1969_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/COC.0b013e3182940ff9","volume":"38","author":"AT Wild","year":"2015","unstructured":"Wild AT, Ye X, Ellsworth SG, et al. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol. 2015;38:259\u201365.","journal-title":"Am J Clin Oncol"},{"key":"1969_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/cgt.2016.65","volume":"24","author":"M Pergamo","year":"2017","unstructured":"Pergamo M, Miller G. Myeloid-derived suppressor cells and their role in pancreatic cancer. Cancer Gene Ther. 2017;24:100\u20135.","journal-title":"Cancer Gene Ther"},{"key":"1969_CR12","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1038\/onc.2013.257","volume":"33","author":"SM W\u00f6rmann","year":"2014","unstructured":"W\u00f6rmann SM, Diakopoulos KN, Lesina M, et al. The immune network in pancreatic cancer development and progression. Oncogene. 2014;33:2956\u201367.","journal-title":"Oncogene"},{"key":"1969_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ctrv.2019.06.005","volume":"78","author":"A Henriksen","year":"2019","unstructured":"Henriksen A, Dyhl-Polk A, Chen I, et al. Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev. 2019;78:17\u201330.","journal-title":"Cancer Treat Rev"},{"key":"1969_CR14","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med"},{"key":"1969_CR15","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.ijrobp.2006.03.018","volume":"66","author":"LK Mell","year":"2006","unstructured":"Mell LK, Kochanski JD, Roeske JC, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:1356\u201365.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR16","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.ijrobp.2007.08.074","volume":"70","author":"LK Mell","year":"2008","unstructured":"Mell LK, Schomas DA, Salama JK, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:1431\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR17","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.21037\/jtd.2020.03.93","volume":"12","author":"NB Newman","year":"2020","unstructured":"Newman NB, Anderson JL, Sherry AD, et al. Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer. J Thorac Dis. 2020;12:2395\u2013405.","journal-title":"J Thorac Dis"},{"key":"1969_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ijrobp.2015.09.022","volume":"94","author":"MP Deek","year":"2016","unstructured":"Deek MP, Benenati B, Kim S, et al. Thoracic vertebral body irradiation contributes to acute hematologic toxicity during chemoradiation therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2016;94:147\u201354.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13014-017-0824-x","volume":"12","author":"J Liu","year":"2017","unstructured":"Liu J, Zhao Q, Deng W, et al. Radiation-related lymphopenia is associated with spleen irradiation dose during radiotherapy in patients with hepatocellular carcinoma. Radiat Oncol. 2017;12:90.","journal-title":"Radiat Oncol"},{"key":"1969_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ijrobp.2016.10.046","volume":"97","author":"AS Chadha","year":"2017","unstructured":"Chadha AS, Liu G, Chen H-C, et al. Does unintentional splenic radiation predict outcomes after pancreatic cancer radiation therapy? Int J Radiat Oncol Biol Phys. 2017;97:323\u201332.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR21","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 18 Sept 2021."},{"key":"1969_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2307\/3577549","volume":"123","author":"N Nakamura","year":"1990","unstructured":"Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res. 1990;123:224\u20137.","journal-title":"Radiat Res"},{"key":"1969_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","volume":"94","author":"AT Wild","year":"2016","unstructured":"Wild AT, Herman JM, Dholakia AS, et al. Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2016;94:571\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/COC.0000000000000263","volume":"41","author":"M Alagappan","year":"2018","unstructured":"Alagappan M, Pollom EL, von Eyben R, et al. Albumin and neutrophil-lymphocyte ratio (NLR) predict survival in patients with pancreatic adenocarcinoma treated with SBRT. Am J Clin Oncol. 2018;41:242\u20137.","journal-title":"Am J Clin Oncol"},{"key":"1969_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.radonc.2021.02.035","volume":"158","author":"AR Wolfe","year":"2021","unstructured":"Wolfe AR, Siedow M, Nalin A, et al. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic cancer. Radiother Oncol. 2021;158:207\u201314.","journal-title":"Radiother Oncol"},{"key":"1969_CR26","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.3892\/ol.2015.4057","volume":"11","author":"S Hasegawa","year":"2016","unstructured":"Hasegawa S, Eguchi H, Tomokuni A, et al. Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer. Oncol Lett. 2016;11:1560\u20136.","journal-title":"Oncol Lett"},{"key":"1969_CR27","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.1016\/j.ijrobp.2016.06.974","volume":"96","author":"AL Pearson","year":"2016","unstructured":"Pearson AL, Jin W, Mellon EA, et al. Post-stereotactic body radiation therapy (SBRT) neutrophil-to-lymphocyte ratio (NLR) in patients with borderline resectable pancreatic cancer (BRPC) may be a prognostic biomarker. Int J Radiat Oncol Biol Phys. 2016;96:E153.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR28","doi-asserted-by":"publisher","first-page":"342","DOI":"10.5009\/gnl17216","volume":"12","author":"BM Lee","year":"2018","unstructured":"Lee BM, Chung SY, Chang JS, et al. The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are prognostic factors in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Gut Liver. 2018;12:342\u201352.","journal-title":"Gut Liver"},{"key":"1969_CR29","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","volume":"21","author":"L Mart\u00ednez-Lostao","year":"2015","unstructured":"Mart\u00ednez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21:5047\u201356.","journal-title":"Clin Cancer Res"},{"key":"1969_CR30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1186\/s12885-019-6220-1","volume":"19","author":"G Wu","year":"2019","unstructured":"Wu G, Baine MJ, Zhao N, et al. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer. BMC Cancer. 2019;19:977.","journal-title":"BMC Cancer"},{"key":"1969_CR31","doi-asserted-by":"crossref","unstructured":"Reyngold M, O\u2019Reilly EM, Varghese AM, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer. JAMA Oncol. 2021.","DOI":"10.1001\/jamaoncol.2021.0057"},{"key":"1969_CR32","first-page":"9691067","volume":"2019","author":"H-G Zhang","year":"2019","unstructured":"Zhang H-G, Yang P, Jiang T, et al. Lymphopenia is associated with gross target volumes and fractions in hepatocellular carcinoma patients treated with external beam radiation therapy and also indicates worse overall survival. Can J Gastroenterol Hepatol. 2019;2019:9691067.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1969_CR33","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","volume":"89","author":"C Tang","year":"2014","unstructured":"Tang C, Liao Z, Gomez D, et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014;89:1084\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.radonc.2020.07.052","volume":"154","author":"TB Brunner","year":"2021","unstructured":"Brunner TB, Haustermans K, Huguet F, et al. ESTRO ACROP guidelines for target volume definition in pancreatic cancer. Radiother Oncol. 2021;154:60\u20139.","journal-title":"Radiother Oncol"},{"key":"1969_CR35","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/j.prro.2019.07.018","volume":"10","author":"A Oar","year":"2020","unstructured":"Oar A, Lee M, Le H, et al. Australasian gastrointestinal trials group (AGITG) and trans-Tasman radiation oncology group (TROG) guidelines for pancreatic stereotactic body radiation therapy (SBRT). Pract Radiat Oncol. 2020;10:e136\u201346.","journal-title":"Pract Radiat Oncol"},{"key":"1969_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1748-717X-7-86","volume":"7","author":"L Caravatta","year":"2012","unstructured":"Caravatta L, Sallustio G, Pacelli F, et al. Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer. Radiat Oncol. 2012;7:86.","journal-title":"Radiat Oncol"},{"issue":"21","key":"1969_CR37","first-page":"02600","volume":"S0360\u20133016","author":"JA Miller","year":"2021","unstructured":"Miller JA, Toesca DAS, Baclay JRM, et al. Pancreatic stereotactic body radiation therapy with or without hypofractionated elective nodal irradiation. Int J Radiat Oncol Biol Phys. 2021;S0360\u20133016(21):02600\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR38","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.18632\/oncotarget.27727","volume":"11","author":"ES Katayama","year":"2020","unstructured":"Katayama ES, Hue JJ, Bajor DL, et al. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Oncotarget. 2020;11:3489\u2013501.","journal-title":"Oncotarget"},{"key":"1969_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41571-019-0281-6","volume":"17","author":"C Nevala-Plagemann","year":"2020","unstructured":"Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020;17:108\u201323.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01969-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-021-01969-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01969-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T18:08:31Z","timestamp":1640369311000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-021-01969-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1969"],"URL":"https:\/\/doi.org\/10.1186\/s13014-021-01969-1","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"25 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was retrospective in nature and did not involve human\/subject experimentation\/interaction. There was an ethical review process for collection of data by our institutional review board (IRB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JMH is former employee of PANCAN and current employee of 1440 Foundation. No other conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}